Contemporary Use and Implications of Beta-Blockers in Patients With HFmrEF or HFpEF
JACC: Heart Failure · 2024-04 · 12 (4) · 631-644
DOI: 10.1016/j.jchf.2023.09.007 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JACC: Heart Failure, 2024-04. Verfasst von Alexander Peikert und 18 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Heart Failure, Ventricular Dysfunction, Left, Benzhydryl Compounds, Glucosides. Die Arbeit wurde bisher 48-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca Gothenburg.
Abstract (Originalsprache)
BACKGROUND: Although beta-blockers are not recommended for the treatment of heart failure with preserved ejection fraction (HFpEF) according to the latest European Society of Cardiology and American Heart Association/American College of Cardiology/Heart Failure Society of America guidelines, these therapies remain commonly used for comorbidity management. There has been concern that beta-blockers may adversely influence clinical outcomes by limiting chronotropic response in HFpEF. OBJECTIVES: This study sought to examine the contemporary use and implications of beta-blockers in patients with heart failure with mildly reduced ejection fraction (HFmrEF) or HFpEF. METHODS: In the DELIVER (Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure) trial, a total of 6,263 patients with symptomatic heart failure (HF) with a left ventricular ejection fraction (LVEF) >40% were randomized to dapagliflozin or placebo across 20 countries. In this prespecified analysis, efficacy and safety outcomes were examined according to beta-blocker use at randomization. The primary outcome was cardiovascular death or worsening HF. RESULTS: Overall, beta-blockers were used in 5,177 patients (83%), with wide variation by geographic region. Beta-blocker use was associated with a lower risk of the primary outcome in covariate-adjusted models (HR: 0.70; 95% CI: 0.60-0.83). Dapagliflozin consistently reduced the risk of the primary outcome in patients taking beta-blockers (HR: 0.82; 95% CI: 0.72-0.94) and in patients not taking beta-blockers (HR: 0.79; 95% CI: 0.61-1.03; Pinteraction = 0.85), with similar findings for key secondary endpoints. Adverse events were balanced between patients randomized to dapagliflozin and placebo, regardless of background beta-blocker use. CONCLUSIONS: In patients with HFmrEF or HFpEF who were enrolled in DELIVER, 4 out of 5 participants were treated with a beta-blocker. Beta-blocker use was not associated with a higher risk of worsening HF or cardiovascular death. Dapagliflozin consistently and safely reduced clinical events, irrespective of background beta-blocker use. (Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure [DELIVER]; NCT03619213).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
- Minneapolis VA Center for Care Delivery and Outcomes Research, Division of Cardiology, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
- Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City, Kansas City, Missouri, USA.
- BHF Glasgow Cardiovascular Research Center, School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, Scotland, United Kingdom.
- National Heart Centre Singapore & Duke-National University of Singapore, Singapore; Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
- Yale School of Medicine, New Haven, Connecticut, USA.
Förderung
- AstraZeneca Gothenburg
Zitieren
APA
Peikert, A., Bart, B. A., Vaduganathan, M., Claggett, B. L., Kulac, I. J., Kosiborod, M. N., Desai, A. S., Jhund, P. S., Lam, C. S. P., Inzucchi, S. E., Martinez, F. A., de Boer, R. A., Hernandez, A. F., Shah, S. J., Petersson, M., Langkilde, A. M., McMurray, J. J. V., Solomon, S. D., & Vardeny, O. (2024). Contemporary Use and Implications of Beta-Blockers in Patients With HFmrEF or HFpEF. JACC: Heart Failure, 12(4), 631-644. https://doi.org/10.1016/j.jchf.2023.09.007
Vancouver
Peikert A, Bart BA, Vaduganathan M, Claggett BL, Kulac IJ, Kosiborod MN, et al. Contemporary Use and Implications of Beta-Blockers in Patients With HFmrEF or HFpEF. JACC: Heart Failure. 2024;12(4):631-644. doi:10.1016/j.jchf.2023.09.007
BibTeX
@article{Peikert2024,
author = {Peikert, Alexander and Bart, Bradley A and Vaduganathan, Muthiah and Claggett, Brian L and Kulac, Ian J and Kosiborod, Mikhail N and Desai, Akshay S and Jhund, Pardeep S and Lam, Carolyn S P and Inzucchi, Silvio E and Martinez, Felipe A and de Boer, Rudolf A and Hernandez, Adrian F and Shah, Sanjiv J and Petersson, Magnus and Langkilde, Anna Maria and McMurray, John J V and Solomon, Scott D and Vardeny, Orly},
title = {Contemporary Use and Implications of Beta-Blockers in Patients With HFmrEF or HFpEF},
journal = {JACC: Heart Failure},
year = {2024},
volume = {12},
number = {4},
pages = {631--644},
doi = {10.1016/j.jchf.2023.09.007}
}
EUVIMED